Table 1.

Response to novel agents of interest.

Pt ID	Regimen	Prior lines Rx, N	Dx to NAOI Rx, months	Duration of Rx, months	TTNT, months	Hematologic	VEGF	PET	Clinical
5	Dd	2^a,b	35	2	4	SD	NA	NA	PD
10	Dd	3^b	129	42^c		VGPR	NA	PR	NA
14	DRd	4	125	12^c		CR	CR	NA	NA
8	DRd	1^b	100	13^c		NA	CR	CR	NA
6	DRd	3^a,b	47	15		CR	CR	NE	CR
4	DRd	1^a,b	16	31^c		NA	NA	CR	CR
11	DRd	1^b	138	37		CR	CR	CR	PR
2	DRd	1	27	56^c		VGPR	CR	CR	CR
16	DPd	5^a	46	1		SD	SD	SD	SD
13	DPd	2^b	24	30	31	CR	NA	CR	CR
9	DPd	3^a,b	135	32^c		VGPR	NA	PR	SD
7	DPd	3^b	53	46		CR	CR	NA	SD
3	DCd	1^b	19	3		NA	CR	NA	CR
16	DCd	3^a	36	4	7	SD	NA	NA	SD
1	DVCd	1^a	22	3	4	VGPR	NA	NA	CR
1	DPVd	2^a	26	16		SD	SD	NA	SD
9	Kd	2^a,b	86	28	49	VGPR	NA	PR	SD
12	Kd	4^a,b	141	57^c		CR	CR	NA	CR
13	KRd	1^b	22	2	3	NA	NA	PD	PD
16	KRd	2^a	31	5	6	PR	NA	NA	PD
15	KRd	1	165	16^c		NA	NA	PR	SD
5	KPd	3^a,b	38	36^c		CR	NA	NA	SD
12	Pd	2^a,b	116	2	3	PD	PD	NA	PD
16	ERd	4^a	43	2	3	SD	SD	SD	SD

Bold rows refer to non-responding regimen/patient.

C cyclophosphamide, CR complete response, D daratumumab, d dexamethasone, Dx diagnosis, E elotuzomab, K carfilzomib, mo months, NA not assessed, P pomalidomide, PD progressive disease, PR partial response, Pt patient, R lenalidomide, Rx therapy, SD stable disease, TTNT time to next therapy, V bortezomib, VEGF vascular endothelial growth factor, VGPR very good partial response.

^aPatients who received prior lenalidomide.

^bPatients who had prior ASCT.

^cTherapy is ongoing.